Department of Pharmacy Practice, Oregon State University College of Pharmacy, Portland, Oregon, USA.
Oregon Health & Science University School of Nursing, Portland, Oregon, USA.
J Palliat Med. 2022 Dec;25(12):1790-1794. doi: 10.1089/jpm.2021.0630. Epub 2022 Jun 1.
High-quality hospice care is characterized by patient-centered care and shared decision making between patients, families, and health care workers. However, little is known regarding the frequency and characteristics of patient and family participation in medication decisions on transition to hospice care. To quantify the frequency and characteristics of patient and/or family participation in medication decisions. Adult (age ≥18 years) patients discharged from Oregon Health & Science University Hospital (OHSU) to hospice care between January 1, 2010 and December 31, 2016. Cross-sectional study. The primary outcome was documented patient and/or family participation. Patient or family participation was defined as documentation of patient or family member discussion surrounding medication decisions in the discharge summary. We used logistic regression to identify patient and admission characteristics associated with documentation of patient or family member participation in medication decisions. Among 348 eligible patients, patient and/or family participation was documented in 22% of discharges to hospice care. Higher Charlson comorbidity index (adjusted odds ratio [aOR]: 1.09, 95% confidence interval [CI]: 1.01-1.17) and having a diagnosis of cancer (aOR: 1.99, 95% CI: 1.16-3.43) were associated with an increased documentation of patient or family member participation in medication decisions. Patients admitted to the intensive care unit were less likely to have patient/family member participation (aOR: 0.55, 95% CI: 0.32-0.94). Having a specialty palliative care consultation was not significantly associated with patient or family member participation in medication decisions (aOR: 0.77, 95% CI: 0.40-1.48). Patient or family participation in medication decisions was documented for only 22% patients on discharge to hospice care. Opportunities to improve participation likely include increasing knowledge and capacity regarding primary palliative care for all clinicians and implementation of specialized interventions for patients and families transitioning to hospice care from acute care settings.
高质量的临终关怀以患者为中心的护理和患者、家庭和医疗保健工作者之间的共同决策为特征。然而,对于患者和家属在过渡到临终关怀时参与药物决策的频率和特征知之甚少。为了量化患者和/或家属参与药物决策的频率和特征。年龄≥18 岁的成年患者(从俄勒冈健康与科学大学医院(OHSU)出院至 2010 年 1 月 1 日至 2016 年 12 月 31 日接受临终关怀)。横断面研究。主要结果是记录的患者和/或家属参与情况。患者或家属参与被定义为在出院小结中记录患者或家属就药物决策进行讨论的情况。我们使用逻辑回归来确定与记录患者或家属参与药物决策相关的患者和入院特征。在 348 名符合条件的患者中,22%的患者在临终关怀出院时记录了患者和/或家属的参与情况。较高的 Charlson 合并症指数(调整后的优势比[aOR]:1.09,95%置信区间[CI]:1.01-1.17)和癌症诊断(aOR:1.99,95%CI:1.16-3.43)与记录患者或家属参与药物决策的可能性增加相关。入住重症监护病房的患者不太可能有患者/家属参与(aOR:0.55,95%CI:0.32-0.94)。接受专科姑息治疗咨询与患者或家属参与药物决策无显著相关性(aOR:0.77,95%CI:0.40-1.48)。只有 22%的临终关怀出院患者的药物决策记录了患者或家属的参与。提高参与率的机会可能包括提高所有临床医生对主要姑息治疗的认识和能力,并为从急症护理环境过渡到临终关怀的患者和家庭实施专门干预措施。